Urinary Tract Infections and Antibiotic Intervention, 2nd Edition

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotics Use and Antimicrobial Stewardship".

Deadline for manuscript submissions: 10 December 2025 | Viewed by 936

Special Issue Editor


E-Mail Website
Guest Editor
Department of Urology, Wake Forest School of Medicine, Winston-Salem, NC, USA
Interests: urinary microbiome; UTI; UTI in kidney stone patients; improvement of devices used in urinary tract; antibiotic stewardship in UTI
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The first edition of the Special Issue on “Urinary Tract Infections and Antibiotic Intervention”, published in 2023, is a successful collection of seven excellent papers and, as such, has encouraged us to open a second edition covering the same topic.

As a continuation of the first Special Issue, this second edition aims to increase our understanding of the urinary microbiome and its relationship with different disease conditions, clarifying the treatment indications for UTIs with different symptom levels, antibiotic overuse and its detrimental effects, superbugs, and antibiotic stewardship in UTIs.

The topics may include but are not limited to the following:

  • urinary tract infections (UTIs);
  • antibiotic use;
  • urinary microbiome;
  • urinary sepsis;
  • next-generation sequencing and urine culture.

Dr. Majid Mirzazadeh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • UTI
  • antibiotic
  • microbiome
  • PCR
  • next-generation sequencing
  • urine culture
  • enhanced quantitative urine cultures
  • urinary sepsis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 371 KB  
Article
Clinical Impact of Treating Versus Not Treating Asymptomatic Bacteriuria/Candiduria in the First Two Months After Kidney Transplantation
by Biagio Pinchera, Rosa Carrano, Isabella Di Filippo, Vincenzo Fotticchia, Mariangela Petrone, Francesco Antimo Alfè, Gianmarco Borriello, Amerigo Piccione, Fabrizio Salemi and Ivan Gentile
Antibiotics 2025, 14(11), 1155; https://doi.org/10.3390/antibiotics14111155 - 14 Nov 2025
Viewed by 465
Abstract
Background/Objectives: The management of asymptomatic bacteriuria (ASB) and candiduria (ASC) in kidney transplant recipients during the early post-transplant period is controversial. This study aimed to evaluate whether treating, versus not treating, ASB and ASC episodes in the first two months after kidney transplantation [...] Read more.
Background/Objectives: The management of asymptomatic bacteriuria (ASB) and candiduria (ASC) in kidney transplant recipients during the early post-transplant period is controversial. This study aimed to evaluate whether treating, versus not treating, ASB and ASC episodes in the first two months after kidney transplantation influences clinical outcomes and the emergence of multidrug-resistant (MDR) infections. Methods: We conducted a single-center retrospective cohort study enrolling patients with ASB or ASC occurring in the first two months after kidney transplantation between January 2019 and July 2024. Patients were classified into treated and untreated groups. The primary endpoint was 30-day mortality. Secondary endpoints included mortality at 90, 180 and 360 days; incidence of sepsis or septic shock; bacteremia/candidemia, hospitalization, graft loss; decline in renal function, urinary tract infections (UTIs), recurrent UTI and rate of MDR colonization/infection. Results: We enrolled 59 kidney transplant recipients and observed 147 episodes of ASB/ASC. Of the 147 episodes, 95 were untreated and 52 were treated. No significant differences were observed between treated and untreated patients in 30-day (2.1% vs. 3.8%) or 90-day mortality (2.1% vs. 1.9%), nor in any of the secondary clinical outcomes. However, patients who received treatment tended to have a higher rate of MDR colonization/infection (63% vs. 46%). MDR pathogen isolation was significantly associated with increased risks of septic shock (OR 4.639, p = 0.04), bacteremia/candidemia (OR 3.734, p = 0.01), hospitalization (OR 2.183, p = 0.03) and renal function deterioration (OR 3.93, p = 0.03). Conclusions: Antimicrobial treatment of ASB and ASC in the early post-transplant period would seem not to confer clinical benefit and may be associated with the risk of MDR colonization/infection. Full article
(This article belongs to the Special Issue Urinary Tract Infections and Antibiotic Intervention, 2nd Edition)
Show Figures

Figure 1

Back to TopTop